Novo Integrated Sciences FY 2024 Financial Overview
Novo Integrated Sciences, Inc. (OTC Pink: NVOS), known for its innovative patient-first approach to health and wellness, has made substantial progress in the fiscal year 2024. The company focuses on a multidisciplinary healthcare ecosystem that ensures patients' needs are at the forefront of service delivery and product innovations.
Commitment to Healthcare Innovation
CEO Robert Mattacchione emphasized the company's ongoing commitment to commercializing proprietary products while enhancing service delivery in a transformative healthcare environment. Special attention is being paid to enhancing their cash position through non-dilutive capital raising strategies and innovative solutions.
Financial Highlights
For the fiscal year that ended in 2024, Novo Integrated Sciences reported notable financial outcomes:
- The company reported cash and cash equivalents of $844,584, with total assets reaching $32,141,276 and stockholders' equity at $14,892,621.
- Total revenue for the year amounted to $13,294,357, marking a 6% increase from $12,572,019 in 2023, primarily driven by increased product sales.
- Operating costs increased by 17% to $15,818,802, affected by factors such as asset impairment and increased overhead expenses.
- Net loss rose to $16,166,744, representing a 22% increase compared to the previous year's loss, attributed to various financial adjustments, including currency exchange losses and amortization of debt discounts.
- In April, Novo executed a $6.21 million Securities Purchase Agreement with Streeterville Capital LLC, securing capital with an annual interest rate of 10.9%, secured by the company's property assets.
- A registration statement for the resale of shares was filed in July, projected to provide liquidity and financial stability.
About Novo Integrated Sciences
Novo Integrated Sciences, Inc. is leading a holistic movement towards decentralized healthcare. The company integrates sophisticated medical technology with advanced therapeutics and rehabilitative science to deliver effective healthcare solutions. This integration supports a shift from traditional healthcare services to more accessible options within the patient's home.
Three Pillars of Transformation
Novo’s operational strategy is constructed around three primary pillars:
- Service Networks: Providing multidisciplinary care through an affiliate network of clinic facilities, including small clinics in commissioned commercial spaces and corporate-operated facilities.
- Technology: Developing and integrating interconnected technologies that connect patients with healthcare providers, effectively expanding service reach.
- Products: Creating personalized health products aimed at preventative care to foster a healthier population.
Through these initiatives, the company believes healthcare can be decentralized, ensuring patients receive the treatment they need without traditional barriers.
Frequently Asked Questions
What are the key financial figures for Novo Integrated Sciences in FY 2024?
The key financial figures include revenues of $13,294,357, a net loss of $16,166,744, and total assets amounting to $32,141,276.
How did Novo Integrated Sciences expand its services in FY 2024?
Novo expanded its services by enhancing its product offerings and improving customer access to care through a decentralized healthcare model.
What is the company's strategy for increasing cash flow?
The company aims to increase cash flow by focusing on non-dilutive funding solutions and enhancing existing service offerings.
What industries does Novo Integrated Sciences operate in?
Novo operates in the healthtech industry, integrating medical technology with therapeutic and wellness solutions.
Where can I find more information about Novo Integrated Sciences?
For more details, please visit the official website of Novo Integrated Sciences.
